sgi-dna, a wholly owned subsidiary of synthetic genomics inc., provides genomic solutions to advance scientific discovery. sgi-dna’s ever expanding suite of products, services, reagents, bioinformatics tools and instrumentation enables scientists to discover, design and build novel solutions for basic research, as well as for biomedical and industrial applications. sgi-dna’s genomic services include whole genome sequencing, dna synthesis, library design, bioinformatics, cell engineering, and plasmid dna cloning and purification. sgi-dna’s reagents include a complete suite of gibson assembly® and site directed mutagenesis kits as well as optimized cell lines such as vmax™ a novel, fast growing host system for molecular biology. to further enable synthetic biology workflows, sgi-dna offers the bioxp™ 3200 system. this fully automated genomics workstation allows the creation of double stranded dna fragments, automated cloning, as well as next generation sequencing dna library preparation.
Company profile
Ticker
TBIO
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Codex DNA, Inc.
SEC CIK
Corporate docs
Subsidiaries
SGI-DNA Limited • EtonBio Inc. ...
IRS number
451216839
TBIO stock data
Latest filings (excl ownership)
8-K
Telesis Bio Announces Reverse Stock Split
6 May 24
ARS
2023 FY
Annual report to shareholders
23 Apr 24
DEF 14A
Definitive proxy
19 Apr 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
PRE 14A
Preliminary proxy
9 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8 Apr 24
S-8
Registration of securities for employees
3 Apr 24
10-K
2023 FY
Annual report
29 Mar 24
8-K
Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 24
8-K
Telesis Bio Announces Select Preliminary
26 Feb 24
Transcripts
TBIO
Earnings call transcript
2023 Q2
10 Aug 23
TBIO
Earnings call transcript
2023 Q1
11 May 23
TBIO
Earnings call transcript
2022 Q4
21 Mar 23
TBIO
Earnings call transcript
2022 Q3
8 Nov 22
TBIO
Earnings call transcript
2022 Q2
14 Aug 22
TBIO
Earnings call transcript
2022 Q2
9 Aug 22
TBIO
Earnings call transcript
2022 Q1
15 May 22
TBIO
Earnings call transcript
2022 Q1
10 May 22
TBIO
Earnings call transcript
2021 Q4
23 Mar 22
TBIO
Earnings call transcript
2021 Q4
22 Mar 22
Latest ownership filings
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 17.57 mm | 17.57 mm | 17.57 mm | 17.57 mm | 17.57 mm | 17.57 mm |
Cash burn (monthly) | 9.74 mm | 612.17 k | 3.54 mm | 3.18 mm | 1.96 mm | 2.75 mm |
Cash used (since last report) | 71.04 mm | 4.47 mm | 25.82 mm | 23.19 mm | 14.32 mm | 20.06 mm |
Cash remaining | -53.47 mm | 13.10 mm | -8.25 mm | -5.62 mm | 3.25 mm | -2.49 mm |
Runway (months of cash) | -5.5 | 21.4 | -2.3 | -1.8 | 1.7 | -0.9 |
Institutional ownership, Q4 2021
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 9 |
Closed positions | 8 |
Increased positions | 20 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 403.36 mm |
Total shares | 34.96 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Northpond Ventures | 9.84 mm | $106.32 mm |
Northpond Ventures | 9.38 mm | $191.82 mm |
TBIO Telesis Bio | 6.00 mm | $0.00 |
DHR Danaher | 2.29 mm | $24.78 mm |
Millennium Management | 1.26 mm | $13.65 mm |
BEN Franklin Resources | 921.59 k | $9.95 mm |
Ophir Asset Management Pty | 917.04 k | $9.90 mm |
TimesSquare Capital Management | 605.00 k | $6.53 mm |
Pura Vida Investments | 572.30 k | $6.18 mm |
ArrowMark Colorado | 563.29 k | $6.08 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 May 24 | Gregory J. Herrema | Common Stock | Grant | Acquire A | No | No | 0 | 31,486 | 0.00 | 184,677 |
1 May 24 | Gregory J. Herrema | Stock Option Common Stock | Grant | Acquire A | No | No | 0.3557 | 30,362 | 10.80 k | 30,362 |
17 Apr 24 | Eric Eugene Esser | Common Stock | Grant | Acquire A | No | No | 0 | 100,000 | 0.00 | 129,260 |
17 Apr 24 | Eric Eugene Esser | Stock Option Common Stock | Grant | Acquire A | No | No | 0.38 | 200,000 | 76.00 k | 200,000 |
27 Feb 24 | Todd Robert Nelson | Common Stock | Payment of exercise | Dispose F | No | No | 0.534 | 4,776 | 2.55 k | 131,296 |
27 Feb 24 | Daniel Glenn Gibson | Common Stock | Payment of exercise | Dispose F | No | No | 0.534 | 2,265 | 1.21 k | 99,818 |
27 Feb 24 | Rob Cutler | Common Stock | Payment of exercise | Dispose F | No | No | 0.534 | 2,174 | 1.16 k | 23,294 |
News
Telesis Bio Announces 1-For-18 Reverse Stock Split, Will Open For Trading On The Nasdaq Global Select Market On May 9, 2024 On A Post-Split Basis
6 May 24
12 Health Care Stocks Moving In Thursday's After-Market Session
25 Apr 24
12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Apr 24
Telesis Bio Inc. Announces Strategic Focus On Game-Changing Gibson Sola Enzymatic DNA Synthesis Platform And BioXp mRNA Solutions; Todd R. Nelson To Step Down As CEO, Eric Esser, President And COO Of Telesis Bio, Will Assume The Role Of The Co's CEP, Effective Immediately
18 Apr 24
12 Health Care Stocks Moving In Tuesday's After-Market Session
16 Apr 24
Press releases
Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership
18 Apr 24
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA
26 Feb 24
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results
26 Feb 24